Baidu
map

Aging Dis:年轻血液有益于年老患者缺血性卒中后的功能恢复

2017-10-08 MedSci MedSci原创

既往研究已经表明,血液中的物质可以大大逆转老化相关的损伤,因为研究发现老年小鼠暴露于年轻血液能够恢复成年干细胞的功能,改善小鼠认知,并可改善其心脏肥大。来自小鼠的全身因素也可以延长暴露于致死性治疗或疾病的伴侣的寿命。这些发现表明,健康的年轻伴侣的系统性环境可能对老年生物有益。然而,未知健康的年轻系统性环境是否可以改善缺血性卒中后的功能恢复。研究发现,与对照组相比,远端大脑中动脉阻塞(dMCAO)引

既往研究已经表明,血液中的物质可以大大逆转老化相关的损伤,因为研究发现老年小鼠暴露于年轻血液能够恢复成年干细胞的功能,改善小鼠认知,并可改善其心脏肥大。

来自小鼠的全身因素也可以延长暴露于致死性治疗或疾病的伴侣的寿命。这些发现表明,健康的年轻伴侣的系统性环境可能对老年生物有益。然而,未知健康的年轻系统性环境是否可以改善缺血性卒中后的功能恢复。

研究发现,与对照组相比,远端大脑中动脉阻塞(dMCAO)引起的缺血性卒中后老年大鼠腹腔内注射年轻血浆可以降低梗死体积和运动障碍。相反,年轻缺血性大鼠腹腔注射老年血浆会使脑损伤和运动缺陷恶化。使用蛋白质组学方法,研究人员发现老年大鼠血清中触珠蛋白的水平可明显升高,缺血性卒中年轻大鼠腹腔注射触珠蛋白可恶化其结局。

总之,该研究结果表明,老化的系统环境在缺血性卒中后的功能结局中起关键作用。

原始出处:

Mengxiong Pan, Peng Wang, et al., Aging Systemic Milieu Impairs Outcome after Ischemic Stroke in Rats. Aging Dis. 2017 Oct; 8(5): 519–530. Published online 2017 Oct 1. doi: 10.14336/AD.2017.0710

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2012434, encodeId=d18f20124343b, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu Jul 12 00:11:00 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756777, encodeId=991d1e56777a1, content=<a href='/topic/show?id=930248998da' target=_blank style='color:#2F92EE;'>#年轻血液#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48998, encryptionId=930248998da, topicName=年轻血液)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3bea37226670, createdName=751943081_32627961, createdTime=Sun Oct 29 02:11:00 CST 2017, time=2017-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892950, encodeId=38f5189295064, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Thu Sep 20 08:11:00 CST 2018, time=2018-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671316, encodeId=54d416e13169e, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Thu Jan 25 15:11:00 CST 2018, time=2018-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806188, encodeId=8d4f18061880c, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sat Jan 06 22:11:00 CST 2018, time=2018-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1599334, encodeId=b2a4159933492, content=<a href='/topic/show?id=5eb4329159a' target=_blank style='color:#2F92EE;'>#功能恢复#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32915, encryptionId=5eb4329159a, topicName=功能恢复)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e9518693674, createdName=mnda, createdTime=Tue Oct 10 03:11:00 CST 2017, time=2017-10-10, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2012434, encodeId=d18f20124343b, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu Jul 12 00:11:00 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756777, encodeId=991d1e56777a1, content=<a href='/topic/show?id=930248998da' target=_blank style='color:#2F92EE;'>#年轻血液#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48998, encryptionId=930248998da, topicName=年轻血液)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3bea37226670, createdName=751943081_32627961, createdTime=Sun Oct 29 02:11:00 CST 2017, time=2017-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892950, encodeId=38f5189295064, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Thu Sep 20 08:11:00 CST 2018, time=2018-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671316, encodeId=54d416e13169e, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Thu Jan 25 15:11:00 CST 2018, time=2018-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806188, encodeId=8d4f18061880c, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sat Jan 06 22:11:00 CST 2018, time=2018-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1599334, encodeId=b2a4159933492, content=<a href='/topic/show?id=5eb4329159a' target=_blank style='color:#2F92EE;'>#功能恢复#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32915, encryptionId=5eb4329159a, topicName=功能恢复)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e9518693674, createdName=mnda, createdTime=Tue Oct 10 03:11:00 CST 2017, time=2017-10-10, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2012434, encodeId=d18f20124343b, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu Jul 12 00:11:00 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756777, encodeId=991d1e56777a1, content=<a href='/topic/show?id=930248998da' target=_blank style='color:#2F92EE;'>#年轻血液#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48998, encryptionId=930248998da, topicName=年轻血液)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3bea37226670, createdName=751943081_32627961, createdTime=Sun Oct 29 02:11:00 CST 2017, time=2017-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892950, encodeId=38f5189295064, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Thu Sep 20 08:11:00 CST 2018, time=2018-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671316, encodeId=54d416e13169e, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Thu Jan 25 15:11:00 CST 2018, time=2018-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806188, encodeId=8d4f18061880c, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sat Jan 06 22:11:00 CST 2018, time=2018-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1599334, encodeId=b2a4159933492, content=<a href='/topic/show?id=5eb4329159a' target=_blank style='color:#2F92EE;'>#功能恢复#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32915, encryptionId=5eb4329159a, topicName=功能恢复)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e9518693674, createdName=mnda, createdTime=Tue Oct 10 03:11:00 CST 2017, time=2017-10-10, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2012434, encodeId=d18f20124343b, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu Jul 12 00:11:00 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756777, encodeId=991d1e56777a1, content=<a href='/topic/show?id=930248998da' target=_blank style='color:#2F92EE;'>#年轻血液#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48998, encryptionId=930248998da, topicName=年轻血液)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3bea37226670, createdName=751943081_32627961, createdTime=Sun Oct 29 02:11:00 CST 2017, time=2017-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892950, encodeId=38f5189295064, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Thu Sep 20 08:11:00 CST 2018, time=2018-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671316, encodeId=54d416e13169e, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Thu Jan 25 15:11:00 CST 2018, time=2018-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806188, encodeId=8d4f18061880c, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sat Jan 06 22:11:00 CST 2018, time=2018-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1599334, encodeId=b2a4159933492, content=<a href='/topic/show?id=5eb4329159a' target=_blank style='color:#2F92EE;'>#功能恢复#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32915, encryptionId=5eb4329159a, topicName=功能恢复)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e9518693674, createdName=mnda, createdTime=Tue Oct 10 03:11:00 CST 2017, time=2017-10-10, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2012434, encodeId=d18f20124343b, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu Jul 12 00:11:00 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756777, encodeId=991d1e56777a1, content=<a href='/topic/show?id=930248998da' target=_blank style='color:#2F92EE;'>#年轻血液#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48998, encryptionId=930248998da, topicName=年轻血液)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3bea37226670, createdName=751943081_32627961, createdTime=Sun Oct 29 02:11:00 CST 2017, time=2017-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892950, encodeId=38f5189295064, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Thu Sep 20 08:11:00 CST 2018, time=2018-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671316, encodeId=54d416e13169e, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Thu Jan 25 15:11:00 CST 2018, time=2018-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806188, encodeId=8d4f18061880c, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sat Jan 06 22:11:00 CST 2018, time=2018-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1599334, encodeId=b2a4159933492, content=<a href='/topic/show?id=5eb4329159a' target=_blank style='color:#2F92EE;'>#功能恢复#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32915, encryptionId=5eb4329159a, topicName=功能恢复)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e9518693674, createdName=mnda, createdTime=Tue Oct 10 03:11:00 CST 2017, time=2017-10-10, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2012434, encodeId=d18f20124343b, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu Jul 12 00:11:00 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756777, encodeId=991d1e56777a1, content=<a href='/topic/show?id=930248998da' target=_blank style='color:#2F92EE;'>#年轻血液#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48998, encryptionId=930248998da, topicName=年轻血液)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3bea37226670, createdName=751943081_32627961, createdTime=Sun Oct 29 02:11:00 CST 2017, time=2017-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892950, encodeId=38f5189295064, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Thu Sep 20 08:11:00 CST 2018, time=2018-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671316, encodeId=54d416e13169e, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Thu Jan 25 15:11:00 CST 2018, time=2018-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806188, encodeId=8d4f18061880c, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sat Jan 06 22:11:00 CST 2018, time=2018-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1599334, encodeId=b2a4159933492, content=<a href='/topic/show?id=5eb4329159a' target=_blank style='color:#2F92EE;'>#功能恢复#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32915, encryptionId=5eb4329159a, topicName=功能恢复)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e9518693674, createdName=mnda, createdTime=Tue Oct 10 03:11:00 CST 2017, time=2017-10-10, status=1, ipAttribution=)]
    2017-10-10 mnda

相关资讯

缺血性卒中脑侧支循环评估与干预中国指南(2017)

中国卒中学会脑血流与代谢分会组织国内来自于神经内科、神经介入及放射、神经外科、神经影像、基础研究及部分工程类和计算机专家,在2013年“缺血性卒中侧支循环评估与干预中国专家共识”的基础上组织讨论并撰写了本指南。 本指南参照中国卒中学会指南制定标准与规范撰写,旨在总结目前国内外研究结果,推广新的概念及临床证据、提高对脑侧支循环临床意义的理解,推动脑侧支循环的规范评估与治疗。

STROKE:γ-谷氨酰转移酶与缺血性卒中的死亡率密切相关!

近期,一项发表在杂志STROKE上的研究的旨在评估入院时血清γ-谷氨酰转移酶(GGT)浓度与急性缺血性卒中患者1年全因或心血管疾病(CVD)死亡率的关系。此项前瞻性多中心队列研究在中国的4个卒中中心进行。研究者们检测了基线时GGT的水平。在为期1年的随访中检查了GGT与全因死亡或CVD死亡风险的关系。此项研究共记录了5912例中风患者的相关数据。在这些患者中,51.0%为男性,中位年龄为61岁。在

STROKE:如何预测缺血性卒中伴随房颤患者的出血风险?

目前,对于心房颤动和先前的短暂性脑缺血发作或缺血性卒中患者的大出血风险评分的效果尚未明确。近期,一项发表在杂志STROKE上的研究旨在验证大出血风险评分在脑缺血后服用口服抗凝剂治疗房颤的患者的效果,并探讨口服抗凝剂在出血风险类别中的净效益。研究者们共分析了3623例RE-LY试验中(随机评估长期抗凝治疗)患有短暂性脑缺血发作或中风史的患者。使用C统计学和校准图评估了HEMORR2HAGES(肝脏或

Stroke:CADASIL患者大脑微出血与缺血性卒中风险有何关系!

由此可见,微出血的存在是CADASIL患者发生缺血性卒中的一个独立危险标志,这一发现强调了需要仔细解读MRI数据。

Neurology:80岁以上的急性缺血性卒中溶栓时间对预后的影响

研究认为,对80岁以上的急性缺血性卒中患者,溶栓治疗在3小时后会略微影响患者预后,但组间的绝对差异较小。

JAMA Neurol:吡格列酮可降低缺血性卒中或短暂性脑缺血后复发风险

对于缺血性卒中或短暂性脑缺血后复发风险高的患者,服用吡格列酮可显著降低其复发风险,但同时增加患者的骨折风险

Baidu
map
Baidu
map
Baidu
map